Media stories about Rockwell Medical (NASDAQ:RMTI) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rockwell Medical earned a news impact score of 0.11 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.1108625885539 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Rockwell Medical (NASDAQ:RMTI) remained flat at $6.33 during mid-day trading on Tuesday. 115,740 shares of the stock traded hands. Rockwell Medical has a 12-month low of $3.55 and a 12-month high of $8.98. The firm’s market cap is $327.51 million. The stock’s 50-day moving average is $6.61 and its 200 day moving average is $6.99.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). The business had revenue of $13.24 million during the quarter, compared to the consensus estimate of $13.05 million. Rockwell Medical had a negative return on equity of 42.22% and a negative net margin of 39.68%. The business’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the company earned ($0.11) EPS. On average, equities analysts expect that Rockwell Medical will post ($0.44) EPS for the current fiscal year.

Several analysts have weighed in on RMTI shares. BidaskClub cut Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research raised Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Ifs Securities started coverage on Rockwell Medical in a report on Monday, August 14th. They issued a “strong-buy” rating and a $11.00 price target on the stock. Finally, ValuEngine cut Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.38.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Rockwell Medical (RMTI) Share Price” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-rockwell-medical-rmti-share-price.html.

Rockwell Medical Company Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Insider Buying and Selling by Quarter for Rockwell Medical (NASDAQ:RMTI)

Receive News & Stock Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related stocks with our FREE daily email newsletter.